This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Written by Kim Callender, NP, FNP-BC·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Prices verified July 12, 2026·Methodology v1.0

Regulatory updates: compounded GLP-1

The legal status of compounded semaglutide and tirzepatide has changed more in eighteen months than in the previous decade. This page tracks it, with dates and sources.

Current status

Routine compounding of semaglutide and tirzepatide is no longer lawful on the basis that created the market. The FDA declared both shortages resolved, and enforcement discretion ended for every class of compounder between February 18 and May 22, 2025. Courts upheld the FDA. On April 30, 2026 the agency proposed excluding all three molecules from the 503B bulks list. Claims that compounding achieved "permanent legitimacy" through 503A/503B are false.

The timeline

FDA compounding timeline for semaglutide and tirzepatide — every date sourced to an FDA order or court decision
Date	What happened	Why it matters
March 2022	Semaglutide (Wegovy) added to the FDA drug shortage list.	Shortage begins — the legal window for compounding opens.
August 2022	Ozempic (semaglutide) added to the shortage list.
December 15, 2022	Tirzepatide (Mounjaro, Zepbound) added to the shortage list.	Compounded tirzepatide becomes lawful under the shortage exception.
October 2, 2024	FDA declares the tirzepatide shortage resolved.	The legal basis for compounding tirzepatide as an 'essentially a copy' drug begins to close.
December 19, 2024	FDA reaffirms the tirzepatide resolution in a declaratory order.	Sets a 60-day (503A) / 90-day (503B) transition.
February 18, 2025	503A enforcement discretion for tirzepatide ENDS.	State-licensed pharmacies must stop compounding tirzepatide copies.
February 21, 2025	FDA removes semaglutide from the shortage list.
March 19, 2025	503B enforcement discretion for tirzepatide ENDS.	Outsourcing facilities must stop compounding tirzepatide copies.
April 22, 2025	503A enforcement discretion for semaglutide ENDS.
April 24, 2025	Court denies the Outsourcing Facilities Association's injunction (semaglutide).	OFA v. FDA, N.D. Tex. — FDA's determination stands.
May 7, 2025	Court upholds FDA on tirzepatide in OFA v. FDA.	The shortage-exception route is closed for both molecules.
May 22, 2025	503B enforcement discretion for semaglutide ENDS.	All shortage-based compounding of both molecules is now outside enforcement discretion.
April 30, 2026	FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.	Finding: no clinical need for outsourcing facilities to compound them from bulk. Comment period closed June 29, 2026.

The rule that governs it

The "essentially a copy" rule

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act bar compounders from producing drugs that are essentially a copy of a commercially available FDA-approved product. While a drug sits on the FDA shortage list, that bar is lifted. Once the shortage is resolved, it snaps back.

Why every provider suddenly sells "personalized" and "microdose" doses

With the shortage exception gone, one narrow route remains open to 503A pharmacies: a compounded product is not considered 'essentially a copy' if the prescriber determines, and documents on the prescription, that the change produces a significant clinical difference for that individual patient. This is the legal mechanism — not a clinical breakthrough — behind the sudden, industry-wide appearance of "personalized dosing" and "microdose" GLP-1 programs. Changing the strength so it is not "the same, similar, or easily substitutable" as an approved dose is what keeps the product outside the copy definition.

Patients should understand what that means in practice: the dose you are offered may have been chosen partly to satisfy a regulatory test, not purely a clinical one. FDA's own guidance gives examples of a genuine clinical difference — removing an inactive ingredient because of a documented patient allergy, or switching a tablet to a liquid for a patient who cannot swallow — and expressly notes such changes are not necessarily applicable to GLP-1 drugs. That is a pointed signal about how much weight the agency gives this workaround.

Enforcement and litigation riskEli Lilly and Novo Nordisk are actively litigating against telehealth companies, medical spas and compounding pharmacies marketing compounded copies, and have sent cease-and-desist letters across the sector. Enforcement risk is not theoretical, and it falls on the provider — but a provider that is forced to stop mid-course leaves the patient without continuity of supply.

What is still live

Two things. First, the FDA's 503B bulks-list proposal of April 30, 2026 — which found no clinical need for outsourcing facilities to compound these molecules from bulk — was still in process after its June 29, 2026 comment deadline. If finalised, it closes the 503B route entirely.

Second, litigation continues. Eli Lilly and Novo Nordisk are actively pursuing telehealth companies, medical spas and compounding pharmacies, and have issued cease-and-desist letters across the sector.

This page will ageTreat any page on this topic — including this one — as time-sensitive. This is the fastest-moving area we cover, and a page that was accurate in March may not be accurate in September.

What it means for patients

The risk you carry is not legal exposure — it is continuity of supply. If your pharmacy is forced to stop, your medication stops, potentially mid-titration. Ask any provider what its contingency plan is, and note that the collapse in brand pricing has narrowed the reason to carry that risk at all.

The finding most comparison sites will not printThe economic case for compounded GLP-1 has narrowed sharply, and almost no comparison site says so. In 2023 the choice was roughly $1,000+/month for brand versus $150–$300 for compounded — a gap wide enough to justify real regulatory risk. As of July 12, 2026, brand Zepbound is $299–$449 through LillyDirect, brand Wegovy is $349 (or $149 for the oral tablet) through NovoCare, and both drop to roughly $25 with commercial coverage. Meanwhile compounded programs advertise $99–$299.

For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.

Sources

U.S. Food and Drug Administration — Declaratory Order: Resolution of Shortage of Tirzepatide Injection Products (December 19, 2024).
U.S. Food and Drug Administration — Declaratory Order: Resolution of Shortage of Semaglutide Injection Products (February 2025).
U.S. Food and Drug Administration — Guidance on compounded drug products that are essentially copies under section 503A.
U.S. Food and Drug Administration — Proposed exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026).
Outsourcing Facilities Association v. FDA, N.D. Tex. — injunction denied April 24 and May 7, 2025.

Spotted an error? Submit a correction.

SURMOUNT-1 — mean body-weight reduction by tirzepatide dose, 72 weeks

Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.